This study will assess the impact of 2-drug (DA) or 3-drug (IDA) regimens on lymphatic filariasis infection parameters in communities. Parameters measured will include: circulating filarial antigenemia (CFA) assessed with the Filariasis Test Strip (FTS), antifilarial antibodies tested with plasma and microfilaremia (assessed by night blood smears and microscopy).
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Number of participants with circulating filarial antigenemia (CFA) as measured by the Filaria Test Strip
Timeframe: One sample collected about 12 months after exposure to treatment
Number of participants with IgG4 antifilarial antibodies in plasma
Timeframe: One sample collected about 12 months after exposure to treatment
Number of participants with microfilaremia as measured with night blood smear testing
Timeframe: One sample collected about 12 months after exposure to treatment